tirzepatide subscription New Access and Pricing Through Self-Pay Options FDA approves tirzepatide, Eli Lilly's

Recently, first clinical observations have emerged suggesting that GLP-1RAs may improve inflammatory skin diseases, including psoriasis [18], hidradenitis suppurativa [19], and atopic dermatitis [20], but the pathophysiologic pathways behind these observations remain speculative

OMalley D, Reimann F, Simpson AK, Gribble FM

Yes, if tirzepatide remains ineffective after optimization of dose, adherence, and lifestyle factors, switching to alternative GLP-1 receptor agonists like semaglutide or adding complementary diabetes medications may be appropriate

For all these reasons, prospective, controlled and randomized studies are warranted to advance our knowledge of the effects of these agents in KT recipients

Extending intervals allows GLP-1 receptor activity to drop, triggering hunger rebound and weight regain